Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager

Although immune checkpoint blockade therapies have shown evidence of clinical effectiveness in many types of cancer, the outcome of clinical trials shows that very few patients with colorectal cancer benefit from treatments with checkpoint inhibitors. Bispecific T cell engagers (TCEs) are gaining po...

Descripción completa

Detalles Bibliográficos
Autores principales: Anbari, Samira, Wang, Hanwen, Zhang, Yu, Wang, Jun, Pilvankar, Minu, Nickaeen, Masoud, Hansel, Steven, Popel, Aleksander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318535/
https://www.ncbi.nlm.nih.gov/pubmed/37408756
http://dx.doi.org/10.3389/fphar.2023.1163432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318535/
https://www.ncbi.nlm.nih.gov/pubmed/37408756
http://dx.doi.org/10.3389/fphar.2023.1163432

Ejemplares similares